Exelixis
EXEL
#1488
Rank
โ‚น1.393 T
Marketcap
โ‚น5,623
Share price
0.78%
Change (1 day)
53.29%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น302.96

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น317.79. In 2025 the company made an earnings per share (EPS) of โ‚น278.31.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น302.968.86%
2025โ‚น278.31
2023โ‚น62.9114.61%
2022โ‚น54.89-22.97%
2021โ‚น71.26100%
2020โ‚น35.63-65.09%
2019โ‚น102.08-53.91%
2018โ‚น221.49333.96%
2017โ‚น51.04-260.61%
2016-โ‚น31.78-58.75%
2015-โ‚น77.04-42.45%
2014-โ‚น133.865.3%
2013-โ‚น127.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น841.06 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น73.19-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,562 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น183.25-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น121.87-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น437.20 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น307.93-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น1,369-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น80.89-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA